Completed and ongoing CVOTs (6–14,39,44–58)

Slides:

Advertisements

Similar presentations

Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin.

Advertisements

Dr John Cox Diabetes in Primary Care Conference Cork

Mikhail Kosiborod, MD Professor of Medicine (Cardiology)

LEADER trial: Primary Outcome

Assessment of Achieved Clinic and Ambulatory Blood Pressure Recordings and Outcomes During Treatment in Hypertensive Patients With CKD: A Multicenter.

Neal B, et al. Diabetes Care 2015;38:403–411

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Assessment of Achieved Clinic and Ambulatory Blood Pressure Recordings and Outcomes During Treatment in Hypertensive Patients With CKD: A Multicenter.

Nat. Rev. Nephrol. doi: /nrneph

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

Updates on CVOT Data and Clinical Comparisons That Matter

Figure 6 Differences in glycaemic control with the study drug

Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?

Updates on Outcomes for Novel T2D Therapies

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

SGLT2 Inhibitors and CV Outcomes

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.

PCSK9 Inhibitors and Cardiovascular Outcomes

EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

LEADER One Year On.

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Antihyperglycemic Therapy

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

CV Outcomes and Adherence With GLP-1 RAs

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Need for better diabetes treatment for improved renal outcome

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.

Baseline Characteristics of the Subjects*

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future

Incidence rates and HRs for total cardiovascular events and stroke stratified by the TCF7L2-rs polymorphism and the dietary intervention group after.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.

Glucose-lowering medication in type 2 diabetes: overall approach.

The incidence of insulin-treated type 1 diabetes in the first 35 years of life. The incidence of insulin-treated type 1 diabetes in the first 35 years.

Shown are cumulative incidence curves of TNNHS and DPT-1 participants who either had DPTRS values >7.00 (A) or dysglycemia (B). Shown are cumulative incidence.

Algorithm for the management of patients with prediabetes or T2DM and definite NASH. This suggested therapeutic algorithm is based on the safety and efficacy.

What's New in Oral Combination Therapy for Type 2 Diabetes?

Emerging Advances in Reducing Renal Complications of T2D

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

Baseline predictors of acute complication of diabetes among immigrants with language barriers (N = 87,707). *Adjustment for all variables listed, as well.

Baseline predictors for risk of cardiovascular events or all-cause mortality among immigrants with language barriers (N = 87,707). *Adjustment for all.

Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.

John J.V. McMurray et al. JCHF 2018;6:8-17

Evolution of prospectively planned primary end points in completed CVOTs of antihyperglycemic treatments for type 2 diabetes, listed in order of year of.

Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)

ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.

Distribution of daily frequency of BGM

A1C at baseline, 16 weeks, and 32 weeks according to study group in all participants (A), adult participants (B), and adolescent participants (C) who returned.

Prevalence of nephropathy, retinopathy, and neuropathy in subjects achieving all (A) three targets, (B) two targets, (C) one target, and (D) none, and.

Kaplan-Meier survival (renal event-free) curves during follow-up by tertiles of plasma copeptin. Kaplan-Meier survival (renal event-free) curves during.

RR (with 95% CI) of total mortality (multivariate-adjusted) by duration of smoking cessation among diabetic women. RR (with 95% CI) of total mortality.

Glucose-lowering medication in type 2 diabetes: overall approach.

The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

Schematic depiction of three stages of the natural history of T2D, noting several opportunities for improvement of management. Schematic depiction of three.

A: Glucose levels during basal-bolus and SSI treatment.

Cumulative mean numbers of confirmed (plasma glucose ≤3

Presentation transcript:

Completed and ongoing CVOTs (6–14,39,44–58) Completed and ongoing CVOTs (6–14,39,44–58). 3-P, 3-point; 4-P, 4-point; 5-P, 5-point. Completed and ongoing CVOTs (6–14,39,44–58). 3-P, 3-point; 4-P, 4-point; 5-P, 5-point. DECLARE-TIMI 58, Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events; ESRD, end-stage renal disease; HARMONY Outcomes, Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus; PIONEER 6, A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes; REWIND, Researching Cardiovascular Events With a Weekly Incretin in Diabetes; VERTIS CV, Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease. William T. Cefalu et al. Dia Care 2018;41:14-31 ©2018 by American Diabetes Association